APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Generic Drugs

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Selected research

Market Analysis & Forecast

Global Generic Drugs Market Analysis and Forecast 2026-2032

Report ID 17399476021 January 2026219 pages

Choose your research edition.

Industry ResearchGeneric Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Generic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic Drugs Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.

North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.

Read the full market overview

Report Includes

This report presents an overview of global market for Generic Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Generic Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Generic Drugs revenue, projected growth trends, production technology, application and end-user industry.

Generic Drugs Segment by Company

Teva

Novartis - Sandoz

Mylan

Sun Pharmaceutical

Aspen

Fresenius Kabi

Pfizer (Hospira)

Sanofi

Aurobindo

Lupin

Dr. Reddy's

Apotex

Cipla

ENDO (Par Pharmaceutical)

Stada Arzneimittel

Krka Group

Nichi-Iko Pharmaceutical

Valeant

Zydus Cadila

Hikma

Pharmaniaga Berhad

Hovid Berhad

Duopharma Biotech

Kotra Pharma

HOE Pharmaceutical

Y.S.P. Industries

Generic Drugs Segment by Type

Prescription

Non-Prescription Drugs

Generic Drugs Segment by Application

Hospital

Clinic

Others

Generic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Generic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Generic Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Generic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prescription Major Player Table 3. Non-Prescription Drugs Major Player Table 4. Global Generic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Others Major Player Table 8. Generic Drugs Industry Trends Table 9. Generic Drugs Industry Drivers Table 10. Generic Drugs Industry Opportunities and Challenges Table 11. Generic Drugs Industry Restraints Table 12. Global Generic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Generic Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Generic Drugs Market Share by Region (2021-2026) Table 15. Global Generic Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Generic Drugs Market Share by Region (2027-2032) Table 17. Global Generic Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Generic Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Generic Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Generic Drugs Key Players Headquarters & Area Served Table 21. Global Generic Drugs Players, Product Type & Application Table 22. Global Generic Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Generic Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Generic Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Generic Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Generic Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Generic Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Generic Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Generic Drugs Revenue Market Share by Application (2027-2032) Table 35. Teva Company Information Table 36. Teva Business Overview Table 37. Teva Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Generic Drugs Product Portfolio Table 39. Teva Recent Development Table 40. Novartis - Sandoz Company Information Table 41. Novartis - Sandoz Business Overview Table 42. Novartis - Sandoz Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis - Sandoz Generic Drugs Product Portfolio Table 44. Novartis - Sandoz Recent Development Table 45. Mylan Company Information Table 46. Mylan Business Overview Table 47. Mylan Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Mylan Generic Drugs Product Portfolio Table 49. Mylan Recent Development Table 50. Sun Pharmaceutical Company Information Table 51. Sun Pharmaceutical Business Overview Table 52. Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sun Pharmaceutical Generic Drugs Product Portfolio Table 54. Sun Pharmaceutical Recent Development Table 55. Aspen Company Information Table 56. Aspen Business Overview Table 57. Aspen Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Aspen Generic Drugs Product Portfolio Table 59. Aspen Recent Development Table 60. Fresenius Kabi Company Information Table 61. Fresenius Kabi Business Overview Table 62. Fresenius Kabi Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Fresenius Kabi Generic Drugs Product Portfolio Table 64. Fresenius Kabi Recent Development Table 65. Pfizer (Hospira) Company Information Table 66. Pfizer (Hospira) Business Overview Table 67. Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer (Hospira) Generic Drugs Product Portfolio Table 69. Pfizer (Hospira) Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sanofi Generic Drugs Product Portfolio Table 74. Sanofi Recent Development Table 75. Aurobindo Company Information Table 76. Aurobindo Business Overview Table 77. Aurobindo Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Aurobindo Generic Drugs Product Portfolio Table 79. Aurobindo Recent Development Table 80. Lupin Company Information Table 81. Lupin Business Overview Table 82. Lupin Generic Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Lupin Generic Drugs Product Portfolio Table 84. Lupin Recent Development Table 85. Dr. Reddy's Company Information Table 86. Dr. Reddy's Business Overview Table 87. Dr. Reddy's Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 88. Dr. Reddy's Generic Drugs Product Portfolio Table 89. Dr. Reddy's Recent Development Table 90. Apotex Company Information Table 91. Apotex Business Overview Table 92. Apotex Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 93. Apotex Generic Drugs Product Portfolio Table 94. Apotex Recent Development Table 95. Cipla Company Information Table 96. Cipla Business Overview Table 97. Cipla Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 98. Cipla Generic Drugs Product Portfolio Table 99. Cipla Recent Development Table 100. ENDO (Par Pharmaceutical) Company Information Table 101. ENDO (Par Pharmaceutical) Business Overview Table 102. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 103. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio Table 104. ENDO (Par Pharmaceutical) Recent Development Table 105. Stada Arzneimittel Company Information Table 106. Stada Arzneimittel Business Overview Table 107. Stada Arzneimittel Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 108. Stada Arzneimittel Generic Drugs Product Portfolio Table 109. Stada Arzneimittel Recent Development Table 110. Krka Group Company Information Table 111. Krka Group Business Overview Table 112. Krka Group Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 113. Krka Group Generic Drugs Product Portfolio Table 114. Krka Group Recent Development Table 115. Nichi-Iko Pharmaceutical Company Information Table 116. Nichi-Iko Pharmaceutical Business Overview Table 117. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 118. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio Table 119. Nichi-Iko Pharmaceutical Recent Development Table 120. Valeant Company Information Table 121. Valeant Business Overview Table 122. Valeant Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 123. Valeant Generic Drugs Product Portfolio Table 124. Valeant Recent Development Table 125. Zydus Cadila Company Information Table 126. Zydus Cadila Business Overview Table 127. Zydus Cadila Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 128. Zydus Cadila Generic Drugs Product Portfolio Table 129. Zydus Cadila Recent Development Table 130. Hikma Company Information Table 131. Hikma Business Overview Table 132. Hikma Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 133. Hikma Generic Drugs Product Portfolio Table 134. Hikma Recent Development Table 135. Pharmaniaga Berhad Company Information Table 136. Pharmaniaga Berhad Business Overview Table 137. Pharmaniaga Berhad Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 138. Pharmaniaga Berhad Generic Drugs Product Portfolio Table 139. Pharmaniaga Berhad Recent Development Table 140. Hovid Berhad Company Information Table 141. Hovid Berhad Business Overview Table 142. Hovid Berhad Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 143. Hovid Berhad Generic Drugs Product Portfolio Table 144. Hovid Berhad Recent Development Table 145. Duopharma Biotech Company Information Table 146. Duopharma Biotech Business Overview Table 147. Duopharma Biotech Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 148. Duopharma Biotech Generic Drugs Product Portfolio Table 149. Duopharma Biotech Recent Development Table 150. Kotra Pharma Company Information Table 151. Kotra Pharma Business Overview Table 152. Kotra Pharma Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 153. Kotra Pharma Generic Drugs Product Portfolio Table 154. Kotra Pharma Recent Development Table 155. HOE Pharmaceutical Company Information Table 156. HOE Pharmaceutical Business Overview Table 157. HOE Pharmaceutical Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 158. HOE Pharmaceutical Generic Drugs Product Portfolio Table 159. HOE Pharmaceutical Recent Development Table 160. Y.S.P. Industries Company Information Table 161. Y.S.P. Industries Business Overview Table 162. Y.S.P. Industries Generic Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 163. Y.S.P. Industries Generic Drugs Product Portfolio Table 164. Y.S.P. Industries Recent Development Table 165. North America Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 166. North America Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 167. North America Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 168. North America Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 169. North America Generic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. North America Generic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 171. North America Generic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 172. Europe Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 173. Europe Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 174. Europe Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 175. Europe Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 176. Europe Generic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 177. Europe Generic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 178. Europe Generic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 179. China Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 180. China Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 181. China Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 182. China Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 183. Asia Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 184. Asia Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 185. Asia Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 186. Asia Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 187. Asia Generic Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 188. Asia Generic Drugs Revenue by Region (US$ Million) & (2021-2026) Table 189. Asia Generic Drugs Revenue by Region (US$ Million) & (2027-2032) Table 190. SAMEA Generic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 191. SAMEA Generic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 192. SAMEA Generic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 193. SAMEA Generic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 194. SAMEA Generic Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. SAMEA Generic Drugs Revenue by Country (2021-2026) & (US$ Million) Table 196. SAMEA Generic Drugs Revenue by Country (US$ Million) & (2027-2032) Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. Generic Drugs Image Figure 2. Global Generic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prescription Image Figure 5. Non-Prescription Drugs Image Figure 6. Global Generic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Generic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Generic Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Generic Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Generic Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Generic Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Generic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Generic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Generic Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Generic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Generic Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Generic Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Generic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Generic Drugs Revenue Share by Type (2021-2032) Figure 24. North America Generic Drugs Revenue Share by Application (2021-2032) Figure 25. North America Generic Drugs Revenue Share by Country (2021-2032) Figure 26. United States Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Generic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Generic Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Generic Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Generic Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Generic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Generic Drugs Revenue Share by Type (2021-2032) Figure 43. China Generic Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Generic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Generic Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Generic Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Generic Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Generic Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Generic Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Generic Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Generic Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Generic Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription
  • Non-Prescription Drugs
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva
  • Novartis - Sandoz
  • Mylan
  • Sun Pharmaceutical
  • Aspen
  • Fresenius Kabi
  • Pfizer (Hospira)
  • Sanofi
  • Aurobindo
  • Lupin
  • Dr. Reddy's
  • Apotex
  • Cipla
  • ENDO (Par Pharmaceutical)
  • Stada Arzneimittel
  • Krka Group
  • Nichi-Iko Pharmaceutical
  • Valeant
  • Zydus Cadila
  • Hikma
  • Pharmaniaga Berhad
  • Hovid Berhad
  • Duopharma Biotech
  • Kotra Pharma
  • HOE Pharmaceutical
  • Y.S.P. Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Generic Drugs Market by Type
  3. 1.2.1 Global Generic Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prescription
  5. 1.2.3 Non-Prescription Drugs
  6. 1.3 Generic Drugs Market by Application
  7. 1.3.1 Global Generic Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Generic Drugs Market Dynamics
  1. 2.1 Generic Drugs Industry Trends
  2. 2.2 Generic Drugs Industry Drivers
  3. 2.3 Generic Drugs Industry Opportunities and Challenges
  4. 2.4 Generic Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Generic Drugs Market Perspective (2021-2032)
  2. 3.2 Global Generic Drugs Growth Trends by Region
  3. 3.2.1 Global Generic Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Generic Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Generic Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Generic Drugs Revenue by Players
  2. 4.1.1 Global Generic Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Generic Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Generic Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Generic Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Generic Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Generic Drugs Players, Product Type & Application
  8. 4.5 Global Generic Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Generic Drugs Market CR5 and HHI
  11. 4.6.3 2025 Generic Drugs Tier 1, Tier 2, and Tier 3
5 Generic Drugs Market Size by Type
  1. 5.1 Global Generic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Generic Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Generic Drugs Revenue Market Share by Type (2021-2032)
6 Generic Drugs Market Size by Application
  1. 6.1 Global Generic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Generic Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Generic Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Generic Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Generic Drugs Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Novartis - Sandoz
  8. 7.2.1 Novartis - Sandoz Company Information
  9. 7.2.2 Novartis - Sandoz Business Overview
  10. 7.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
  12. 7.2.5 Novartis - Sandoz Recent Developments
  13. 7.3 Mylan
  14. 7.3.1 Mylan Company Information
  15. 7.3.2 Mylan Business Overview
  16. 7.3.3 Mylan Generic Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mylan Generic Drugs Product Portfolio
  18. 7.3.5 Mylan Recent Developments
  19. 7.4 Sun Pharmaceutical
  20. 7.4.1 Sun Pharmaceutical Company Information
  21. 7.4.2 Sun Pharmaceutical Business Overview
  22. 7.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
  24. 7.4.5 Sun Pharmaceutical Recent Developments
  25. 7.5 Aspen
  26. 7.5.1 Aspen Company Information
  27. 7.5.2 Aspen Business Overview
  28. 7.5.3 Aspen Generic Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Aspen Generic Drugs Product Portfolio
  30. 7.5.5 Aspen Recent Developments
  31. 7.6 Fresenius Kabi
  32. 7.6.1 Fresenius Kabi Company Information
  33. 7.6.2 Fresenius Kabi Business Overview
  34. 7.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fresenius Kabi Generic Drugs Product Portfolio
  36. 7.6.5 Fresenius Kabi Recent Developments
  37. 7.7 Pfizer (Hospira)
  38. 7.7.1 Pfizer (Hospira) Company Information
  39. 7.7.2 Pfizer (Hospira) Business Overview
  40. 7.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
  42. 7.7.5 Pfizer (Hospira) Recent Developments
  43. 7.8 Sanofi
  44. 7.8.1 Sanofi Company Information
  45. 7.8.2 Sanofi Business Overview
  46. 7.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Generic Drugs Product Portfolio
  48. 7.8.5 Sanofi Recent Developments
  49. 7.9 Aurobindo
  50. 7.9.1 Aurobindo Company Information
  51. 7.9.2 Aurobindo Business Overview
  52. 7.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Aurobindo Generic Drugs Product Portfolio
  54. 7.9.5 Aurobindo Recent Developments
  55. 7.10 Lupin
  56. 7.10.1 Lupin Company Information
  57. 7.10.2 Lupin Business Overview
  58. 7.10.3 Lupin Generic Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lupin Generic Drugs Product Portfolio
  60. 7.10.5 Lupin Recent Developments
  61. 7.11 Dr. Reddy's
  62. 7.11.1 Dr. Reddy's Company Information
  63. 7.11.2 Dr. Reddy's Business Overview
  64. 7.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Dr. Reddy's Generic Drugs Product Portfolio
  66. 7.11.5 Dr. Reddy's Recent Developments
  67. 7.12 Apotex
  68. 7.12.1 Apotex Company Information
  69. 7.12.2 Apotex Business Overview
  70. 7.12.3 Apotex Generic Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Apotex Generic Drugs Product Portfolio
  72. 7.12.5 Apotex Recent Developments
  73. 7.13 Cipla
  74. 7.13.1 Cipla Company Information
  75. 7.13.2 Cipla Business Overview
  76. 7.13.3 Cipla Generic Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cipla Generic Drugs Product Portfolio
  78. 7.13.5 Cipla Recent Developments
  79. 7.14 ENDO (Par Pharmaceutical)
  80. 7.14.1 ENDO (Par Pharmaceutical) Company Information
  81. 7.14.2 ENDO (Par Pharmaceutical) Business Overview
  82. 7.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
  84. 7.14.5 ENDO (Par Pharmaceutical) Recent Developments
  85. 7.15 Stada Arzneimittel
  86. 7.15.1 Stada Arzneimittel Company Information
  87. 7.15.2 Stada Arzneimittel Business Overview
  88. 7.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
  90. 7.15.5 Stada Arzneimittel Recent Developments
  91. 7.16 Krka Group
  92. 7.16.1 Krka Group Company Information
  93. 7.16.2 Krka Group Business Overview
  94. 7.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Krka Group Generic Drugs Product Portfolio
  96. 7.16.5 Krka Group Recent Developments
  97. 7.17 Nichi-Iko Pharmaceutical
  98. 7.17.1 Nichi-Iko Pharmaceutical Company Information
  99. 7.17.2 Nichi-Iko Pharmaceutical Business Overview
  100. 7.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
  102. 7.17.5 Nichi-Iko Pharmaceutical Recent Developments
  103. 7.18 Valeant
  104. 7.18.1 Valeant Company Information
  105. 7.18.2 Valeant Business Overview
  106. 7.18.3 Valeant Generic Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Valeant Generic Drugs Product Portfolio
  108. 7.18.5 Valeant Recent Developments
  109. 7.19 Zydus Cadila
  110. 7.19.1 Zydus Cadila Company Information
  111. 7.19.2 Zydus Cadila Business Overview
  112. 7.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Zydus Cadila Generic Drugs Product Portfolio
  114. 7.19.5 Zydus Cadila Recent Developments
  115. 7.20 Hikma
  116. 7.20.1 Hikma Company Information
  117. 7.20.2 Hikma Business Overview
  118. 7.20.3 Hikma Generic Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Hikma Generic Drugs Product Portfolio
  120. 7.20.5 Hikma Recent Developments
  121. 7.21 Pharmaniaga Berhad
  122. 7.21.1 Pharmaniaga Berhad Company Information
  123. 7.21.2 Pharmaniaga Berhad Business Overview
  124. 7.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
  126. 7.21.5 Pharmaniaga Berhad Recent Developments
  127. 7.22 Hovid Berhad
  128. 7.22.1 Hovid Berhad Company Information
  129. 7.22.2 Hovid Berhad Business Overview
  130. 7.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Hovid Berhad Generic Drugs Product Portfolio
  132. 7.22.5 Hovid Berhad Recent Developments
  133. 7.23 Duopharma Biotech
  134. 7.23.1 Duopharma Biotech Company Information
  135. 7.23.2 Duopharma Biotech Business Overview
  136. 7.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Duopharma Biotech Generic Drugs Product Portfolio
  138. 7.23.5 Duopharma Biotech Recent Developments
  139. 7.24 Kotra Pharma
  140. 7.24.1 Kotra Pharma Company Information
  141. 7.24.2 Kotra Pharma Business Overview
  142. 7.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Kotra Pharma Generic Drugs Product Portfolio
  144. 7.24.5 Kotra Pharma Recent Developments
  145. 7.25 HOE Pharmaceutical
  146. 7.25.1 HOE Pharmaceutical Company Information
  147. 7.25.2 HOE Pharmaceutical Business Overview
  148. 7.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  149. 7.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
  150. 7.25.5 HOE Pharmaceutical Recent Developments
  151. 7.26 Y.S.P. Industries
  152. 7.26.1 Y.S.P. Industries Company Information
  153. 7.26.2 Y.S.P. Industries Business Overview
  154. 7.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
  156. 7.26.5 Y.S.P. Industries Recent Developments
8 North America
  1. 8.1 North America Generic Drugs Revenue (2021-2032)
  2. 8.2 North America Generic Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Generic Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Generic Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Generic Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Generic Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Generic Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Generic Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Generic Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Generic Drugs Revenue by Country
  11. 8.6.1 North America Generic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Generic Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Generic Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Generic Drugs Revenue (2021-2032)
  2. 9.2 Europe Generic Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Generic Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Generic Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Generic Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Generic Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Generic Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Generic Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Generic Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Generic Drugs Revenue by Country
  11. 9.6.1 Europe Generic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Generic Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Generic Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Generic Drugs Revenue (2021-2032)
  2. 10.2 China Generic Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Generic Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Generic Drugs Revenue by Type (2027-2032)
  5. 10.3 China Generic Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Generic Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Generic Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Generic Drugs Revenue by Application (2027-2032)
  9. 10.5 China Generic Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Generic Drugs Revenue (2021-2032)
  2. 11.2 Asia Generic Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Generic Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Generic Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Generic Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Generic Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Generic Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Generic Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Generic Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Generic Drugs Revenue by Country
  11. 11.6.1 Asia Generic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Generic Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Generic Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Generic Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Generic Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Generic Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Generic Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Generic Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Generic Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Generic Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Generic Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Generic Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Generic Drugs Revenue by Country
  11. 12.6.1 SAMEA Generic Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Generic Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Generic Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst